ArticleAustralasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists2025
Open letter to the Medical Services Advisory Committee regarding TMS Item Number regulations.
Article in Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo present the perspective of professionals working in the field of transcranial magnetic stimulation (TMS) regarding the regulations which impact the availability of government subsidisation via Australian Medicare Benefits Schedule Item Number rebates to patients with major depressive disorder (MDD) who are seeking TMS treatment.ConclusionsWe argue that three regulations should be withdrawn: (1) that patients who received TMS prior to 1 November 2021 are ineligible for TMS rebates after 1 November 2021; (2) that every person is subject to a limit of 50 TMS treatments in a lifetime; and (3) that rebates are not available for maintenance TMS. We also conclude that consideration should be given to the provision of rebates for TMS treatments when it is delivered as a first-line treatment for MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.